Incyte Corporation (FRA:ICY)

Market Cap	18.04B
Revenue (ttm)	4.10B
Net Income (ttm)	1.01B
Shares Out	n/a
EPS (ttm)	5.03
PE Ratio	17.81
Forward PE	13.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7
Average Volume	117
Open	90.50
Previous Close	95.56
Day's Range	90.50 - 91.44
52-Week Range	49.00 - 95.56
Beta	n/a
RSI	59.71
Earnings Date	Feb 3, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ICY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD